Huppy hump day, !

This week we dive into the explosive $1.51 trillion-dollar biotech market.

The Global Cardiovascular Devices market keeps growing as heart disease remains the leading cause of death in the US and the elderly population is on the rise.

Devoted Health ($2.25B) and Radiology Partners ($2.06B) lead the pack in healtech startup funding as private equity investors and venture capitalists go all-in on healthcare.

Here’s to a good week and healthy weekend!

-Healthcare 150 Team

Biotech Boom: A Market on the Rise

The biotechnology market is on fire, projected to soar from $1.51 trillion in 2023 to $4.91 trillion by 2033—a staggering 12.2% CAGR. What’s driving this explosive growth? Breakthroughs in gene therapy, personalized medicine, and biologics are revolutionizing healthcare, while agricultural biotech and sustainable solutions are reshaping industries beyond medicine. With funding pouring in and innovation accelerating, the biotech space is proving to be a goldmine for investors and industry leaders alike.

But it hasn’t been all smooth sailing. After a record-breaking $48.3 billion in biotech investments in 2021, funding took a hit, dipping to $18.1 billion in 2023. Why? Macroeconomic headwinds, rising interest rates, and investor caution played a role, but there’s still strong momentum in synthetic biology, precision medicine, and AI-powered drug discovery. With market recalibration underway, savvy investors are eyeing strategic partnerships and later-stage plays to ride the next biotech wave.

Regionally, North America leads the charge, attracting $10.91 billion across 274 deals, while APAC ($3.54 billion) and Europe ($3.29 billion) are gaining traction with government-backed biotech initiatives. Emerging markets—Africa, Latin America, and the Middle East—remain underfunded, but present huge opportunities for biotech expansion as infrastructure and investment frameworks evolve. With massive unmet medical needs, next-gen therapeutics, and deep-pocketed investors ready to deploy capital, biotech is poised for its next breakout decade

Want to learn more?

Premium Perks

Since you are an Executive Subscriber, you get access to all the full length reports our research team makes every week. Interested in learning all the hard data behind the article? If so, this report is just for you.

Want to check the other reports? Access the Report Repository here.

Cardiovascular Devices: A $26B Market in the Making

The heart of the medical device industry is beating stronger than ever. The global cardiovascular devices market, valued at $7.5B in 2024, is projected to more than triple to $26.3B by 2034, growing at a 13.5% CAGR.

What’s driving the surge? A rising elderly population, increasing number of cases of heart disease (17.9M global deaths annually), and the shift toward minimally invasive procedures like catheter-based interventions. AI-powered cardiac monitors and next-gen stents are also fueling demand.

Bottom line: With heart disease still the major cause of death according to the U.S. Centers for Disease Control and Prevention (CDC), the market for cardiovascular devices isn’t just growing—it’s essential.

The $16.8B HealthTech Play

Venture capitalists and private equities are going all-in on healthtech, and the numbers are staggering. Devoted Health ($2.25B) and Radiology Partners ($2.06B) lead the pack, fueling Medicare innovation and AI-powered imaging. Ro ($1B) is rewriting telehealth, while Lyra Health ($906M) is making mental wellness mainstream.

But here's the kicker—funding doesn’t always guarantee success. High-profile crashes like Olive and Forward Health prove that even billion-dollar startups aren’t invincible. The lesson? Healthtech isn’t just about raising cash; it’s about spending it wisely.

Deal of the Week: Cosette Pharma Acquires Mayne for $430M, Expanding Women’s Health & Dermatology

Cosette Pharmaceuticals is making a bold move into women’s health and dermatology, announcing a $430 million acquisition of Australian-based Mayne Pharma. The deal, expected to close in Q2 2025, will add multiple patent-protected products to Cosette’s portfolio, including VYLEESI, INTRAROSA, NEXTSTELLIS, and ANNOVERA, solidifying its leadership in these high-growth therapeutic areas.

The combined company will boast 12 patent-protected products, a global sales force, and two FDA-approved manufacturing facilities in North Carolina and South Australia. Cosette brings 350+ team members, while Mayne adds 480+ employees, creating a commercial powerhouse with expanded R&D and production capabilities. With backing from Avista Healthcare Partners and Hamilton Lane, Cosette is positioning itself as a key player in specialty pharmaceuticals.

With both boards approving the deal and Mayne’s shareholders set to vote, the acquisition marks a transformational expansion for Cosette. As competition in women’s health and dermatology heats up, this deal puts Cosette in a strong position to drive innovation, expand global reach, and improve patient access to critical therapies.

Love Healthcare150? Receive the Same Weekly Newsletter For the Private Equity Market!

PE150 delivers proprietary insights, market trends, and actionable tools for Private Equity & M&A professionals—in just one 5 minute weekly email. Subscribe now

Elderly Care Markets: Regional Opportunities

Aging populations and rising healthcare costs are reshaping global markets, with key regions standing out for elderly care investments.

Japan leads with 28% of its population aged 65+, driving demand for home healthcare, assisted living, and robotics.

The U.S. has 17% aged 65+ but the highest healthcare spending per capita ($9,729+), making it a major market for medical technologies and advanced care models.

Germany (22% aged 65+) combines high spending with a strong social insurance system, supporting long-term care and chronic disease management.

Nordic nations invest $6,000–$8,000 per capita in healthcare, offering opportunities in telemedicine and elder wellness.

Switzerland’s wealthy, aging population fuels demand for premium geriatric care and medical innovations.

💡 Takeaway: These regions are primed for growth in elderly-focused healthcare solutions—where will your next move be?

"Success is not in what you have, but who you are"

Bo Bennett